GenMark has received the issuance notice following a recent audit of the new facility.

All operations at its Pasadena facility, which had been the source of all manufacturing and distribution for the company, will cease at the end of March 2011.

GenMark, a provider of automated, multiplex molecular diagnostic testing systems, detects and measures DNA and RNA targets to diagnose disease and to optimize the treatment of patients and is focused on developing and commercializing its eSensor detection technology.